Inhibitors targeting the catalytic domain of mTOR have also been developed [118], and pre-clinical studies of rapamycin combined with rapalogs targeted at mTOR showed inhibition of clonogenic AML cell proliferation without inhibition of normal CD34+ cells [97]. The gene discussed is MTOR; the disease is acute myeloid leukemia.